is bpc 157 on fda 503a bulks list Exciting news for peptides coming out of today's committee hearing! The Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC- to the for use in compounding for A step towards expanded patient

A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them BPC 157 Just Cleared a Major Regulatory Hurdle If you've been following the peptide world, you've probably heard the buzz about BPC 157. Here's what actually happened: An FDA advisory committee voted to Big decisions could be coming for peptide compounding. Over the next few days, the FDA's Pharmacy Compounding Advisory Committee will discuss several peptides, including BPC 157, and whether they should be considered for BPC 157 PASSED! Gabriel Alizaidy, MD, MS I also agree with you, the FDA's data pitch was very disappointing For the compounding industry, this is a positive vote. It does not immediately make

SKU: 66359694725 · From hgidocs.co